Seyed Moein Moghimi
Overview
Explore the profile of Seyed Moein Moghimi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Moein Moghimi S, Simberg D
Curr Opin Biotechnol
. 2023 Dec;
85:103044.
PMID: 38091875
Immune recognition and uptake of nanoparticles remain the hot topic in nanomedicine research. Complement is the central player in the immune recognition of engineered nanoparticles. Here, we summarize the accumulated...
2.
Hall A, Bartek J, Wagner E, Lachelt U, Moein Moghimi S
J Control Release
. 2023 Aug;
361:115-129.
PMID: 37532151
Recent clinical success with Onpattro and cationic ionizable lipid nanoparticle-based mRNA vaccines has rejuvenated research in the design and engineering of broader synthetic cationic vectors for nucleic acid compaction and...
3.
Moein Moghimi S, McCullough R, Simberg D
Mol Ther
. 2023 Feb;
31(3):605-606.
PMID: 36754053
No abstract available.
4.
Bor G, Lin J, Lin K, Chen H, Prajnamitra R, Salentinig S, et al.
ACS Appl Mater Interfaces
. 2022 Oct;
14(43):48449-48463.
PMID: 36271846
Considering the broad therapeutic potential of omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA), here we study the effect of PEGylation of DHA-incorporated hexosomes on their physicochemical characteristics and...
5.
Moein Moghimi S, Simberg D
Mol Ther
. 2022 Apr;
30(6):2109-2110.
PMID: 35487214
No abstract available.
6.
Bor G, Salentinig S, Sahin E, Nur Odevci B, Roursgaard M, Liccardo L, et al.
J Colloid Interface Sci
. 2021 Aug;
606(Pt 1):464-479.
PMID: 34399363
Lyotropic non-lamellar liquid crystalline (LLC) nanoparticles, with their tunable structural features and capability of loading a wide range of drugs and reporter probes, are emerging as versatile injectable nanopharmaceuticals. Secondary...
7.
Ma Q, Pollard K, Brown J, Italiani P, Moein Moghimi S
Front Immunol
. 2021 Apr;
12:665810.
PMID: 33815427
No abstract available.
8.
Farhangrazi Z, Sancini G, Hunter A, Moein Moghimi S
Front Immunol
. 2020 Oct;
11:579352.
PMID: 33072124
No abstract available.
9.
Yu Helvig S, Woythe L, Pham S, Bor G, Andersen H, Moein Moghimi S, et al.
J Colloid Interface Sci
. 2020 Sep;
582(Pt B):906-917.
PMID: 32919118
Pluronic F127-stabilized non-lamellar liquid crystalline aqueous nanodispersions are promising injectable platforms for drug and contrast agent delivery. These nanodispersions, however, trigger complement activation in the human blood, where the extent...
10.
Pannuzzo M, Esposito S, Wu L, Key J, Aryal S, Celia C, et al.
Nano Lett
. 2020 Apr;
20(6):4312-4321.
PMID: 32259451
Many PEGylated nanoparticles activate the complement system, which is an integral component of innate immunity. This is of concern as uncontrolled complement activation is potentially detrimental and contributes to disease...